107 related articles for article (PubMed ID: 1865748)
1. Diurnal variations of serum beta 2-microglobulin in multiple myeloma.
Pasqualetti P; Casale R; Colantonio D; Collacciani A; Natali G
Life Sci; 1991; 49(6):435-8. PubMed ID: 1865748
[TBL] [Abstract][Full Text] [Related]
2. Circadian rhythm of serum erythropoietin in multiple myeloma.
Pasqualetti P; Collacciani A; Casale R
Am J Hematol; 1996 Sep; 53(1):40-2. PubMed ID: 8813096
[TBL] [Abstract][Full Text] [Related]
3. Chronobiological aspects of phosphohexoseisomerase in monitoring multiple myeloma.
Neri B; Becucci A; Ciapini A; Comparini T; Guidi G; Guidi S
Oncology; 1983; 40(5):332-5. PubMed ID: 6621995
[TBL] [Abstract][Full Text] [Related]
4. Diurnal rhythm of serum erythropoietin circulating levels in chronic obstructive pulmonary disease.
Casale R; Pasqualetti P
Panminerva Med; 1997 Sep; 39(3):183-5. PubMed ID: 9360419
[TBL] [Abstract][Full Text] [Related]
5. Circadian rhythm of serum erythropoietin in myelodysplastic syndromes.
Pasqualetti P; Collacciani A; Casale R
Eur Rev Med Pharmacol Sci; 2000; 4(5-6):111-5. PubMed ID: 11710507
[TBL] [Abstract][Full Text] [Related]
6. No influence of aging on the circadian rhythm of erythropoietin in healthy subjects.
Pasqualetti P; Casale R
Gerontology; 1997; 43(4):206-9. PubMed ID: 9222748
[TBL] [Abstract][Full Text] [Related]
7. Circadian rhythm of serum erythropoietin in healthy subjects.
Pasqualetti P; Casale R
Riv Eur Sci Med Farmacol; 1996; 18(3):91-3. PubMed ID: 9177605
[TBL] [Abstract][Full Text] [Related]
8. [Prognostic importance of beta-2-microglobulin in multiple myeloma].
Avilés A; Zepeda G; Guzmán R; Talavera A; García EL; Díaz-Maqueo JC
Rev Invest Clin; 1992; 44(2):215-20. PubMed ID: 1439309
[TBL] [Abstract][Full Text] [Related]
9. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group.
Seidel C; Børset M; Turesson I; Abildgaard N; Sundan A; Waage A
Blood; 1998 Feb; 91(3):806-12. PubMed ID: 9446640
[TBL] [Abstract][Full Text] [Related]
10. No correlation between response and survival in patients with multiple myeloma treated with vincristine, melphalan, cyclophosphamide, and prednisone.
Baldini L; Radaelli F; Chiorboli O; Fumagalli S; Cro L; Segala M; Cesana BM; Polli EE; Maiolo AT
Cancer; 1991 Jul; 68(1):62-7. PubMed ID: 2049754
[TBL] [Abstract][Full Text] [Related]
11. [Serum beta-2-microglobulin in multiple myeloma. Practical value].
Bataille R; Magub M; Sany J; Donadio D; Izarn P; Grenier J; Suquet P
Rev Rhum Mal Osteoartic; 1981 Mar; 48(3):235-40. PubMed ID: 6164091
[TBL] [Abstract][Full Text] [Related]
12. Beta 2 microglobulin in multiple myeloma.
Alexanian R; Barlogie B; Fritsche H
Am J Hematol; 1985 Dec; 20(4):345-51. PubMed ID: 3907332
[TBL] [Abstract][Full Text] [Related]
13. Alpha interferon raises serum beta-2-microglobulin in patients with multiple myeloma.
Tienhaara A; Remes K; Pelliniemi TT
Br J Haematol; 1991 Mar; 77(3):335-8. PubMed ID: 2012758
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic significance of beta-2-microglobulin in multiple myeloma].
Podol'tseva EI; Morozova EV; Almazov VA
Vopr Onkol; 1996; 42(4):32-5. PubMed ID: 8928455
[TBL] [Abstract][Full Text] [Related]
15. Circadian variations of interleukin-2 receptors, serum thymidine kinase and beta-2-microglobulin in patients with non-Hodgkin's lymphoma and normal controls.
Micke O; Schäfer U; Wörmann B; Hiddemann W; Willich N
Anticancer Res; 1997; 17(4B):3007-10. PubMed ID: 9329587
[TBL] [Abstract][Full Text] [Related]
16. [The prognostic significance of the beta 2-microglobulin level of the blood serum in multiple myeloma patients].
Lubo-Lesnichenko IF; Bessmel'tsev SS; Abdulkadyrov KM; Blinov MN; Stel'mashenko LV
Ter Arkh; 1996; 68(10):28-31. PubMed ID: 9026938
[TBL] [Abstract][Full Text] [Related]
17. Serum syndecan-1: a new independent prognostic marker in multiple myeloma.
Seidel C; Sundan A; Hjorth M; Turesson I; Dahl IM; Abildgaard N; Waage A; Borset M
Blood; 2000 Jan; 95(2):388-92. PubMed ID: 10627439
[TBL] [Abstract][Full Text] [Related]
18. Tumor load in patients with multiple myeloma: β₂-microglobulin levels versus low-dose whole-body CT.
Pfahler V; D'Anastasi M; Dürr HR; Schinner R; Ricke J; Baur-Melnyk A
Eur J Haematol; 2020 May; 104(5):383-389. PubMed ID: 31762076
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of serum thymidine kinase and beta 2 microglobulin in subjects affected by multiple myeloma.
Musolino C; Allegra A; Orlando A; Grosso P; Alonci A; Cincotta M; Squadrito G
Riv Eur Sci Med Farmacol; 1990; 12(4-5):233-8. PubMed ID: 2103961
[TBL] [Abstract][Full Text] [Related]
20. Tumor load in patients with multiple myeloma: β2-microglobulin levels versus whole-body MRI.
D'Anastasi M; Notohamiprodjo M; Schmidt GP; Dürr HR; Reiser MF; Baur-Melnyk A
AJR Am J Roentgenol; 2014 Oct; 203(4):854-62. PubMed ID: 25247952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
